Table 1.
Characteristics of study cohort*
| Characteristics | Primary androgen deprivation therapy, n = 11 749 |
Surveillance, n = 18 026 |
|---|---|---|
| Age, yr, median (IQR) | 80 (75–84) | 77 (72–81) |
| Black race , no. (%) | 1131 (9.6) | 2163 (12.0) |
| Married at diagnosis , no. (%) | 6758 (57.5) | 10 837 (60.1) |
| Urban residence , no. (%) | 9654 (82.2) | 15 247 (84.6) |
| Income, US $ , median (IQR) | 45 361 (35 773–59 436) | 46 118 (35 733–60 306) |
| SEER regions , no. (%) | ||
| Northeast | 1701 (14.5) | 2216 (12.3) |
| North central | 3916 (33.3) | 5214 (28.9) |
| West | 5739 (48.8) | 9765 (54.2) |
| South | 393 (3.3) | 831 (4.6) |
| Cancer risk , no. (%) | ||
| Low risk | 6927 (59.0) | 15 296 (84.9) |
| High risk | 4822 (41.0) | 2703 (15.1) |
| Clinical stage at diagnosis , no. (%) | ||
| T1 | 3568 (30.4) | 8832 (49.0) |
| T2 | 8181 (69.6) | 9194 (51.0) |
| Charlson comorbidity score , no. (%) | ||
| 0–1 | 10 487 (89.3) | 16 386 (90.9) |
| ≥2 | 1262 (10.7) | 1640 (9.1) |
| Year of cancer diagnosis , no. (%) | ||
| 1992–1999 | 5638 (48.0) | 10 218 (56.7) |
| 2000–2007 | 6111 (52.0) | 7808 (43.3) |
| Survive 5 y r, no. (%) | 6355 (54.1) | 11 516 (63.9) |
| Survive 10 y r, no. (%) | 1520 (12.9) | 4047 (22.5) |
IQR = interquartile range; SEER = Surveillance Epidemiology and End Results.
*
Race was self-determined by the patients. Clinical extension information provided by SEER was used to determine cancer stage (T1, T2). Charlson comorbidity score was derived from Medicare claims during the year before prostate cancer diagnosis by using a validated algorithm.